Clinical Trials Logo

Filter by:
NCT ID: NCT00472771 Withdrawn - Clinical trials for Small Cell Lung Cancer

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.

NCT ID: NCT00472628 Withdrawn - Sepsis Clinical Trials

Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)

MINDSET
Start date: May 2007
Phase: N/A
Study type: Observational

The purpose of the study is to procure blood samples from patients ≥18 years of age who present to the Emergency Department (ED) with at least two of the diagnostic criteria for sepsis. Samples obtained upon enrollment will be used for future testing of the Triage Sepsis Panel and other biomarkers.

NCT ID: NCT00472355 Withdrawn - Parkinson's Disease Clinical Trials

Low Dose Apomorphine and Parkinsonism

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if low doses of apomorphine worsen the motor symptoms of Parkinson's disease.

NCT ID: NCT00469625 Withdrawn - Clinical trials for Proteinuric Renal Disease

A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease

Start date: July 2006
Phase: N/A
Study type: Interventional

Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early in CKD, and is undertreated. Vitamin D may have important effects on factors that drive proteinuria and renal disease progression in patients with proteinuric renal diseases. Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.

NCT ID: NCT00469469 Withdrawn - Clinical trials for Adrenocortical Carcinoma

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed nonresectable primary adrenocortical cancer (ACC). Patients must have received no prior therapy. They will receive Bevacizumab as a single agent every 2 weeks intravenously until disease progression. This study will be open at multiple sites.

NCT ID: NCT00469118 Withdrawn - Low Back Pain Clinical Trials

Clinical Efficacy and Safety of Axiom Worldwide DRX9000 Axial Decompression System for Treatment of Low Back Pain

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This study will document efficacy and safety of the Axiom Worldwide DRX9000™ for treatment of low back pain (LBP) in a prospective, randomized, crossover, multicenter trial utilizing a standardized clinical research multimodal protocol. During the first two weeks subjects are randomized to receive either conservative care or DRX treatment first and then cross over to receive either conservative care or DRX treatment the next 6 weeks. This study will test the hypothesis that standardized 6-week treatment regimen of spinal decompression using DRX9000™ will reduce chronic lower back pain more than conservative therapy (current baseline therapy).

NCT ID: NCT00467454 Withdrawn - Pyromania Clinical Trials

Naltrexone in the Treatment of Pyromania

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 10 subjects with pyromania.

NCT ID: NCT00466973 Withdrawn - Atrial Fibrillation Clinical Trials

Atrial Fibrillation Ablation Device Comparison Study

Start date: April 2007
Phase: Phase 4
Study type: Interventional

Atrial fibrillation is an irregular heart rhythm which requires long term anticoagulation to prevent risk of stroke and long term poor outcomes. At the same time one have heart surgery, a small additional procedure can be done to treat atrial fibrillation. Surgeons have a choice of six different devices that he or she can use to treat your atrial fibrillation. It is not known at this point which device is best at treating you, as each device seems to have the same success rate at curing atrial fibrillation. One of the six devices will be selected randomly by card pulled out at the time of enrollment. It is therefore the purpose of this study to compare the devices to each other and to follow up after surgery to determine if any one device is best. This information will be valuable to surgeons and to patients as the treatment for atrial fibrillation develops in the future.

NCT ID: NCT00466908 Withdrawn - Cataract Extraction Clinical Trials

Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery

Start date: March 2007
Phase:
Study type: Observational

The purpose of this study is to determine the accuracy of the Pentacam and IOL Master to calculate the effective corneal power (keratometry, corneal curvature) in patients who have undergone both corneal refractive surgery and lens extraction with intraocular lens implantation.

NCT ID: NCT00466882 Withdrawn - Obesity Clinical Trials

Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients

Start date: October 17, 2005
Phase:
Study type: Observational

The purpose of this study is to assess the use of this Lap-Band system for the purpose of promoting weight loss in renal failure patients who do not qualify as transplant candidates because of excessive BMI's